Announcement • May 12
NexTel Medical Corp Enters Final Stage for Commercial Launch NexTel Medical Corp. announced the commencement of the final stability phase for its inaugural line of commercial exosome products. Last week, NexTel successfully initiated the stability testing phase, a critical precursor to market entry. Under the supervision of Lab Director and Dr. Hausman, a production batch underwent rigorous filtration and diagnostic screening. Utilizing advanced PCR technology, samples were tested for common contaminants, using a threshold of (“0”), including: Shiga-like toxin-producing E. coli, Salmonella, Pseudomonas aeruginosa, Staphylococcus aureus. The samples tested negative for all four organisms. Currently, stability vials are being monitored at both room temperature and refrigeration. Success at the 30-day mark will allow NexTel to proceed with an immediate commercial launch, establishing a definitive shelf life for additive-free, pure exosome products. Announcement • Mar 17
Exousia Pro, Inc. Announces Favorable Litigation Settlement Highlighting Significant Debt Elimination And Share Cancellation To Enhance Shareholder Value Exousia Pro, Inc. had announced the successful settlement of its outstanding litigation involving a former Director. This landmark agreement represents a pivotal financial milestone for the Company, delivering immediate and substantial value to current shareholders by improving the capital structure and strengthening the balance sheet. Under the terms of the settlement, which is expected to close within 30 days, Exousia Pro will make a one-time, strategic payment of $147,500 to the involved parties. In exchange, the Company will secure highly favorable financial restructuring outcomes. For the purposes of the Company’s upcoming financial reporting and audits, these events will be recorded under Generally Accepted Accounting Principles (GAAP) and will provide the following distinct benefits to the Company and its shareholders: Significant Debt Reduction: The settlement triggers the complete cancellation of a $200,000 promissory note issued at closing, as well as the cancellation of the remaining balance on the note tied to the control block of Preferred Stock. Removing these liabilities immediately strengthens Exousia's balance sheet and frees up future cash flow. Reversal of Share Dilution: The agreement secures the cancellation and return to treasury of 6,297,511 shares of Common Stock. Retiring this sizable block of shares reverses prior dilution, directly increasing the equity value, earnings-per-share potential, and ownership percentage of all current shareholders. Enhanced Audit Readiness and Transparency: By formally clearing these contested liabilities and equity issuances from the general ledger under GAAP, the Company is positioned for a clean, streamlined audit. This provides greater financial transparency and reinforces confidence within the investment community. By resolving this legacy dispute efficiently, Exousia Pro’s management team can now focus entirely on advancing its core clinical pipeline and expanding its telehealth initiatives without the distraction or financial overhang of litigation. Announcement • Nov 18
LAMY (OTCPK:LMMY) entered into an agreement to acquire Exousia Ai, Inc. from Marijuana Inc. (OTCPK:MAJI) for $10.6 million. LAMY (OTCPK:LMMY) entered into an agreement to acquire Exousia Ai, Inc. from Marijuana Inc. (OTCPK:MAJI) for $10.6 million on November 11, 2025. For consideration, 62.22 million shares of LAMY common stock will be given to the shareholders of Exousia Ai. The trannsaction was subject to approval from LAMY board and the same was approved.
LAMY (OTCPK:LMMY) completed the acquisition of Exousia Ai, Inc. from Marijuana Inc. (OTCPK:MAJI) on November 17, 2025. 
